Editas Medicine Announces Dosing of First Pediatric Patient

Marks the first-ever in vivo delivery of an experimental CRISPR gene editing medicine to a pediatric patient Company on track to complete dosing of...

Related Keywords

Philadelphia ,Pennsylvania ,United States ,University Of Pennsylvania ,Cambridge ,Cambridgeshire ,United Kingdom ,Irene Heinz ,Albertm Maguire ,Tomass Aleman ,Jamesc Mullen ,European Medicines Agency ,John Laporte Research Associate Professor ,Editas Medicine Inc ,Drug Administration ,Data Monitoring Committee ,Nasdaq ,Irene Heinz Given ,Scheie Eye Institute ,Perelman School ,Pediatric Ophthalmology ,Molecular Ophthalmology ,Advanced Retinal ,Ocular Therapeutics ,Vivo Gene Therapy ,Independent Data Monitoring Committee ,Editas Medicine ,Rare Pediatric Disease ,Orphan Drug ,Orphan Designation ,Congenital Amaurosis ,Nasdaq Edit ,Nc ,